OTC · IONM

Assure Holdings Corp.

Healthcare · Medical - Care Facilities

$0.00

Up+$0.00 (+0.00%)

Updated Aug 16, 2026, 11:38 AM

SID Score

4.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap: 1.61K
P/E ratio: -0
Dividend yield: 0.00%
52-week range: $0.00 – $0.05
Volume: 1.13K
Avg. volume: 16

Price performance

IONM price history

1M range · 0 trading sessions · Daily adjusted prices

Data unavailable

The requested market data was not found.

Latest IONM news

The latest Smart Investors Daily articles mentioning IONM.

No results

No recent SID articles mention IONM.

Latest IONM news

The latest Smart Investors Daily articles mentioning IONM.

Stock researchCompany · Overview

Company

Overview Forecast Earnings Dividend Financials

Market Activity

Options Insider Trades Short Interest Institutional Ownership Sentiment

Research & News

Analysis Competitors News SEC Filings SID Coverage

IONM research

Overview

Company profile and research snapshot.

Company profile

ASSURE HLDGS CORP

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus: —
Average target: $2,217.60
Implied upside: —
Analysts: —

IONM recent ratings
Date	Firm	Rating	Target
Apr 12, 2023	Roth MKM	Buy	—
Apr 6, 2023	Benchmark	Speculative Buy	—
Jun 14, 2022	Roth Capital	Buy	—
Apr 5, 2022	Benchmark	Speculative Buy	—

Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jan 29, 2026

Telo Genomics Announces Appointment of John Price as Chief Financial Officer

Toronto, Ontario--(Newsfile Corp. - January 29, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that John Price has been appointed as Chief Financial Officer, effective immediately. Mr. Price was appointed as Chief Financial Officer effective January 30, 2026. Mr. Price has over three decades of...

defenseworld.net · Dec 7, 2025

Acutus Medical (NASDAQ:AFIB) versus Assure (NASDAQ:IONM) Head to Head Survey

Institutional and Insider Ownership 56.9% of Acutus Medical shares are owned by institutional investors. Comparatively, 3.3% of Assure shares are owned by institutional investors. 5.2% of Acutus Medical shares are owned by company insiders. Comparatively, 3.8% of Assure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By